Loading...
Market
Story
Amgen Receives Accelerated FDA Approval for New Lung Cancer Drug Imdelltra
May 16, 2024, 07:45 PM
Amgen has received accelerated approval from the U.S. Food and Drug Administration (FDA) on Thursday for its new drug, Imdelltra (tarlatamab), designed to treat adult patients with advanced small cell lung cancer (SCLC). This approval is specifically for patients whose disease has progressed despite chemotherapy. Imdelltra is a DLL3-targeting bispecific T-cell engager and represents a significant advancement in the treatment of this aggressive and most deadly form of lung cancer.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Top performer • 33%
Average performer • 34%
Underperformer • 33%
Adopted in over 20 countries • 25%
Adopted in 10-20 countries • 25%
Adopted in less than 10 countries • 25%
Not adopted as standard treatment • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Increase by less than 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%